Potpourri of hot topics from EULAR; abstracts of PsA,SpA, RA, et al
Dr Phil Mease is a Clinical Professor at the University of Washington School of Medicine in Seattle Director of the Rheumatology Clinical Research Division of Swedish Medical Center
His clinical practice is based at Seattle Rheumatology Associates. He conducts clinical trials of emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis and lupus. He conducts research in disease state metrics and is the Co-Chair of three working groups of OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia and single joint assessment, as well as being a member of the Soluble Biomarker working group. He is a founding organizer and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), and a member of SPARTAN (Spondyloarthritis Research & Treatment Network).
6:15 – 7:00 pm Registration
7:00 – 9:00 pm Presentation and dinner
Nieman Marcus, Zodiac Room, Hwy 40 and
This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Washington University School of Medicine, Continuing Medical Education and St. Louis Rheumatology Association. Washington University is accredited by the ACCME to provide continuing medical education for physicians. Washington University designates this live activity for a maximum of _1_ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
All members of the CME department have nothing to disclose. Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations. Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests. These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine. Washington University School of Medicine, Continuing Medical Education, is the sponsor for CME credits.